Diabeton® MR
Gliclazide is intended for the treatment of adults only.
The recommended dose of gliclazide should be taken orally, 1 time per day, preferably during breakfast.
The daily dose can be 30-120 mg ('/g -2 tablets) in one dose.
It is recommended to swallow the tablet or half of the tablet whole, without chewing or crushing.
If you miss one or more doses of the drug, you cannot take a higher dose at the next dose; the missed dose should be taken the next day.
As with other hypoglycemic drugs, the dose of gliclazide in each case must be selected individually, depending on the concentration of blood glucose and HbAlc.
Initial dose
The initial recommended dose (including for elderly patients > 65 years) is 30 mg per day (*/g tablet).
If adequately controlled, gliclazide at this dose can be used for maintenance therapy. If glycemic control is inadequate, the daily dose of gliclazide can be sequentially increased to 60, 90 or 120 mg.
An increase in dose is possible no earlier than after 1 month of therapy with gliclazide at the previously prescribed dose. The exception is patients whose blood glucose concentrations have not decreased after 2 weeks of therapy. In such cases, the dose of gliclazide can be increased 2 weeks after starting treatment.
The maximum recommended daily dose of gliclazide is 120 mg.
1 tablet of the drug Diabeton® MV, modified-release tablets 60 mg, is equivalent to 2 tablets of the drug Diabeton® MV, modified-release tablets 30 mg. The presence of a notch on 60 mg tablets allows you to divide the tablet and take a daily dose of both 30 mg (*/2 60 mg tablets) and, if necessary, 90 mg (1 and '/g 60 mg tablets).
Switching from taking a drug containing gliclazide at a dosage of 80 mg to the drug Diabeton® MB, modified-release tablets, 60 mg
1 tablet of a medicinal product containing gliclazide at a dosage of 80 mg can be replaced */2 tablets of the medicinal product Diabeton® MB 60 mg with modified release. When transferring patients from a drug containing gliclazide at a dosage of 80 mg to the drug Diabeton® MB, careful glycemic control is recommended.
Switching from another hypoglycemic drug to the drug Diabeton® MB, modified-release tablets 60 mg
The drug Diabeton® MV modified release tablets 60 mg can be used instead of another oral hypoglycemic drug. When transferring patients receiving other oral hypoglycemic drugs to the drug Diabeton® MB, their dose and half-life should be taken into account. As a rule, no transition period is required. The initial dose should be 30 mg and then titrated according to blood glucose concentrations.
When replacing sulfonylurea derivatives with a long half-life with the drug Diabeton MB, in order to avoid hypoglycemia caused by the additive effect of two hypoglycemic agents, you can stop taking them for several days. The initial dose of the drug Diabeton® MB is also 30 mg ('/g tablet 60 mg) and, if necessary, can be increased further, as described above.
Combined use with another hypoglycemic drug
The drug Diabeton® MB can be used in combination with biguanides, alpha-glucosidase inhibitors or insulin.
If glycemic control is inadequate, additional insulin therapy should be prescribed with close medical supervision.
Elderly patients
No dose adjustment is required for patients over 65 years of age.
Patients with kidney failure
The results of clinical studies have shown that dose adjustment of the drug is not required in patients with mild to moderate renal failure. Close medical monitoring is recommended.
Patients at risk of developing hypoglycemia
In patients at risk of developing hypoglycemia (insufficient or unbalanced nutrition; severe or poorly compensated endocrine disorders - pituitary and adrenal insufficiency, hypothyroidism; withdrawal of glucocorticosteroids after long-term use and/or use in high doses; severe diseases of the cardiovascular system - severe coronary heart disease, severe atherosclerosis of the carotid arteries, widespread atherosclerosis), it is recommended to use the minimum dose (30 mg) of the drug Diabeton® MB.
Prevention of complications of type 2 diabetes mellitus
To achieve intensive glycemic control, you can gradually increase the dose of Diabeton® MB up to 120 mg/day in addition to diet and exercise until the target HbAlc concentration is achieved. The risk of hypoglycemia should be remembered. In addition, other hypoglycemic drugs, such as metformin, an alpha-glucosidase inhibitor, a thiazolidinedione derivative, or insulin, can be added to therapy.
Children and adolescents under 18 years of age.
There are no data on the effectiveness and safety of the drug in children and adolescents under 18 years of age.
Pharmacodynamics and pharmacokinetics
The main active ingredient is gliclazide . A hypoglycemic drug from the second generation sulfonylurea group. Gliclazide is a sulfonylurea derivative. Contains an azobicyclooctane ring, which significantly distinguishes its mechanism of action from hypoglycemic biguanides and sulfonamides.
The drug also has hemovascular , metabolic and antioxidant effects. Under the influence of Diabeton, the concentration of glucose in the blood decreases (due to the increased production of insulin by special beta cells of the pancreas).
In patients with diabetes mellitus, the drug returns the early peak of insulin and increases the subsequent phase of insulin secretion. An increase in insulin concentration occurs before a meal or glucose load.
The antioxidant and hemovascular effects of drugs reduce the risk of complications of diabetes. Diabeton prevents microthrombosis due to partial inhibition of platelet aggregation and adhesion, and a decrease in the number of platelet activation markers.
The drug increases the activity of tPa and affects the fibrinolytic activity of the endothelial wall of the vessel.
The antioxidant effect of glycoside is achieved by reducing the concentration of lipid peroxides in the blood plasma, increasing the activity of erythrocyte dismutase, plasma thiols, and increasing the total antioxidant capacity.
Gliclazide is metabolized in the liver.
Side effects
With an inadequate diet, violation of the dosage regimen, hypoglycemia , hunger, fatigue, headaches, sweating, rapid heartbeat , insomnia, anxiety , aggressiveness, inattention, visual impairment, paresis , tremor , depression, inattention, aphasia , sensory disturbances, delirium, hypersomnia are noted. , convulsions .
Gastrointestinal tract: dyspeptic disorders, cholestatic jaundice, decreased appetite, increased levels of liver enzymes.
Hematopoietic organs: inhibition of the function of bone marrow hematopoiesis.
Allergy.
Analogues of Diabeton
Level 4 ATC code matches:
Gliclazide
Glidiab
Glyurenorm
Glimepiride
Amyx
Glibenclamide
Amaryl
Maninil
Analogues of the drug include the following drugs: Glidia , Glykinorm , Glyclada , Gliclazide , Glioral , Diaglizide , Dyazid , Panmicron , Reklid .
Which is better: Maninil or Diabeton?
Maninil is considered a more harmful drug.
Diabeton price, where to buy
You can buy a package for about 300 rubles. However, it is now almost impossible to purchase regular Diabeton, since the safer Diabeton MV is mainly sold.
The price of Diabeton in Ukraine is approximately 100-130 UAH.
- Online pharmacies in RussiaRussia
- Online pharmacies in UkraineUkraine
- Online pharmacies in KazakhstanKazakhstan
ZdravCity
- Diabeton mb tab.mod.release.
60 mg 30 pcs OOO Servier Rus 201 rub. order
Pharmacy Dialogue
- Diabeton MV tablets 60 mg No. 30Servier
RUB 215 order
show more
Pharmacy24
- Diabeton MR 60 mg N30 tablets Lab.Serve Industries, France/Serve Industries Ltd., Ireland
103 UAH.order - “Keys of Health” 1.5 g N20 herbal tea diabetonic Keys of Health, Kharkov
28 UAH order
PaniPharmacy
- Diabeton MR tablets Diabeton MR tablets 60 mg No. 30 France, Servier Industrie
103 UAH order
show more
Interaction
H2-histamine receptor blockers, ACE inhibitors, NSAIDs, fibrates, antifungal drugs, coumarin anticoagulants, MAO inhibitors, anabolic steroids, sulfonamides, biguanides, cyclophosphamides, pentoxifylline, theophylline, tetracycline, reserpine , disopyramide , insulin, ethanol , allopurinol enhance the effect of Diabeton .
GCS, barbiturates , antiepileptics, adrenostimulants, BMCC, thiazide diuretics, triamterene, furosemide , baclofen , diazoxide, asparaginase, triamterene, morphine, isoniazid, terbutaline , ritodrine, glucagon, salbutamol, rifampicin, estrogens , chlorpromazine, nicotinic acid weakened affect the effect of the drug.
special instructions
In case of decompensation of diabetes or surgical interventions, insulin intake must be taken into account. Ethanol consumption increases the risk of hypoglycemia.
In case of emotional or physical stress, it is necessary to adjust the dose of the drug Diabeton.
Elderly people and patients with pituitary-adrenal insufficiency are especially sensitive to hypoglycemic drugs.
Slows down the speed of psychomotor reactions.
MNN: Gliclazide.
Reviews about Diabeton
The medicine is characterized as an effective means of lowering blood sugar levels and is convenient to use compared to insulin injections. There are almost no side effects; it may not be suitable for all patients.
Reviews of Diabeton in bodybuilding characterize the drug as a means of increasing weight. However, doctors do not advise using medications and, in particular, Diabeton for purposes other than their intended purpose. This may be hazardous to your health. The use of the medicine can cause hypoglycemia.
